Infections by the Ebola and Marburg filoviruses cause a rapidly fatal haemorrhagic fever in humans for which no approved antivirals are available 1 . Filovirus entry is mediated by the viral spike glycoprotein (GP), which attaches viral particles to the cell surface, delivers them to endosomes and catalyses fusion between viral and endosomal membranes 2 . Additional host factors in the endosomal compartment are probably required for viral membrane fusion; however, despite considerable efforts, these critical host factors have defied molecular identification [3] [4] [5] . Here we describe a genome-wide haploid genetic screen in human cells to identify host factors required for Ebola virus entry. Our screen uncovered 67 mutations disrupting all six members of the homotypic fusion and vacuole protein-sorting (HOPS) multisubunit tethering complex, which is involved in the fusion of endosomes to lysosomes 6 , and 39 independent mutations that disrupt the endo/lysosomal cholesterol transporter protein Niemann-Pick C1 (NPC1) 7 . Cells defective for the HOPS complex or NPC1 function, including primary fibroblasts derived from human Niemann-Pick type C1 disease patients, are resistant to infection by Ebola virus and Marburg virus, but remain fully susceptible to a suite of unrelated viruses. We show that membrane fusion mediated by filovirus glycoproteins and viral escape from the vesicular compartment require the NPC1 protein, independent of its known function in cholesterol transport. Our findings uncover unique features of the entry pathway used by filoviruses and indicate potential antiviral strategies to combat these deadly agents.
We have developed haploid genetic screens to gain insight into the biological processes relevant to human disease 8, 9 . Here we use this approach to explore the filovirus entry pathway at an unprecedented level of detail. To interrogate millions of gene disruption events for defects in Ebola virus entry, we used a replication-competent vesicular stomatitis virus bearing the Ebola virus glycoprotein (rVSV-GP-EboV) 10 . Although this virus replicates in most cell lines, it inefficiently killed near-haploid KBM7 cells ( Supplementary Fig. 1c ). In an unsuccessful attempt to induce pluripotency in KBM7 cells by expression of OCT4 (also called POU5F1), SOX2, MYC and KLF4 (ref. 11) , we obtained HAP1 cells ( Supplementary Fig. 1a ). HAP1 cells grew adherently and no longer expressed haematopoietic markers ( Supplementary Fig. 1b ). Most of these cells in early passage cultures were haploid for all chromosomes, including chromosome 8 (which is diploid in KBM7 cells). Unlike KBM7 cells, HAP1 cells were susceptible to rVSV-GP-EboV ( Supplementary  Fig. 1c ), allowing screens for filovirus host factors.
We used a retroviral gene-trap vector 9 to mutagenize early-passage HAP1 cells. To generate a control data set, we mapped ,800,000 insertions using deep sequencing ( Supplementary Table 1 ). Next, we selected rVSV-GP-EboV-resistant cells, expanded them as a pool, and mapped insertion sites. Enrichment for mutations in genes was calculated by comparing a gene's mutation frequency in resistant cells to that in the control data set ( Supplementary Fig. 2 ). We identified a set of genes enriched for mutations in the rVSV-GP-EboV-resistant cell population ( Fig. 1a, Supplementary Fig. 3 and Supplementary Table 2 ). Nearly all of these candidate host factors are involved in the architecture and trafficking of endo/lysosomal compartments. Our screen identified cathepsin B (CTSB), the only known host factor for which deletion inhibits Ebola virus entry 5 . Further inspection showed that mutations were highly enriched in genes encoding all six subunits of the HOPS complex (VPS11, VPS16, VPS18, VPS33A, VPS39 and VPS41), for which we identified 67 independent mutations. The HOPS complex mediates fusion of endosomes and lysosomes 6 and affects endosome maturation 12, 13 . The identification of all members of the HOPS complex demonstrates high, and possibly saturating, coverage of our screen. We also identified factors involved in the biogenesis of endosomes (PIKFYVE, FIG4) 14 , lysosomes (BLOC1S1, BLOC1S2) 15 , and in targeting of luminal cargo to the endocytic pathway (GNPTAB) 16 . The strongest hit was the Niemann-Pick disease locus NPC1, encoding an endo/lysosomal cholesterol transporter 7 . NPC1 also affects endosome/lysosome fusion and fission 17 , calcium homeostasis 18 and HIV-1 release 19 .
We subcloned the resistant cell population to obtain clones deficient for VPS11, VPS33A and NPC1 ( Supplementary Fig. 4a , b and Fig. 1b ). These mutants displayed marked resistance to infection by rVSV-GP-EboV and VSV pseudotyped with Ebola virus or Marburg virus GP ( Fig. 1c and Supplementary Fig. 4c ). Cells lacking a functional HOPS complex or NPC1 were nonetheless fully susceptible to infection by a large panel of other enveloped and non-enveloped viruses, including VSV and recombinant VSV bearing different viral glycoproteins ( Fig. 1d and Supplementary Fig. 5 ). The susceptibility of HAP1 clones to rVSV-GP-EboV infection was restored by expression of the corresponding cDNAs ( Supplementary Fig. 6a -c).
Loss of NPC1 causes Niemann-Pick disease, a neurovisceral disorder characterized by cholesterol and sphingolipid accumulation in lysosomes 7 . We tested the susceptibility of patient primary fibroblasts to filovirus-GP-dependent infection. NPC1-mutant cells were infected poorly or not at all by rVSV-GP-EboV and VSV pseudotyped with filovirus GP proteins ( Fig. 2a, b ), and infection was restored by expression of wild-type NPC1 (Fig. 2c ).
Mutations in NPC2 cause identical clinical symptoms and phenocopy defects in lipid transport 20 . Surprisingly, NPC2-mutant fibroblasts derived from different patients were susceptible to filovirus-GPdependent infection ( Fig. 2a, b and Supplementary Fig. 7 ), despite a similar accumulation of cholesterol in NPC2-and NPC1-mutant cells ( Fig. 2a ). Moreover, cholesterol clearance from NPC1-null cells by cultivation in lipoprotein-depleted growth medium did not confer susceptibility ( Supplementary Fig. 8 ). Therefore, resistance of NPC1-deficient cells to rVSV-GP-EboV is not caused by defects in cholesterol transport per se.
Filoviruses display broad mammalian host and tissue tropism 21, 22 . To determine if NPC1 is generally required for filovirus-GP-mediated infection, we used Npc1-null Chinese hamster ovary (CHO) cells. Loss of NPC1 conferred complete resistance to viral infection (Supplementary Fig. 6d ) that was reversed by expression of human NPC1 (Supplementary Fig. 6e ). Certain small molecules such as U18666A (ref. 23) and the antidepressant imipramine 24 cause a cellular phenotype similar to NPC1 deficiency possibly by targeting NPC1 (ref. 23 ). Prolonged U18666A treatment has been reported to modestly inhibit VSV 25 . However, we found that brief exposure of Vero cells and HAP1 cells to U18666A or imipramine potently inhibited viral infection mediated by Ebola virus GP but not VSV or rabies virus G ( Fig. 2d and Supplementary Figs 9 and 10). Because U18666A inhibits rVSV-GP-EboV infection only when added at early time points, it probably affects entry rather than replication ( Supplementary Fig. 10 ). Thus, NPC1 has a critical role in infection mediated by filovirus glycoproteins that is conserved in mammals and probably independent of NPC1's role in cholesterol transport.
Filoviruses bind to one or more cell-surface molecules 2,26,27 and are internalized by macropinocytosis 28, 29 . In VPS33A-and NPC1-mutant cells, we observed no significant differences in binding or internalization of Alexa-647-labelled rVSV-GP-EboV ( Fig. 3a and Supplementary Figs 11 and 12a). Similar results were obtained by flow cytometry using fluorescent Ebola-virus-like particles ( Supplementary Fig. 12b ). Moreover, bullet-shaped VSV particles were readily observed by electron microscopy at the cell periphery and within plasma membrane invaginations resembling nascent macropinosomes ( Fig. 3b ). Finally, VPS33A-and NPC1-null cells were fully susceptible to vaccinia virus entry by macropinocytosis ( Supplementary Fig. 13 ). Thus, GPmediated entry is not inhibited at viral attachment or early internalization steps in NPC1-or HOPS-defective cells, indicating a downstream defect.
Cathepsin L (CATL; also called CTSL1)-assisted cleavage of Ebola virus GP by CTSB is required for viral membrane fusion 3, 5 . Mutant HAP1 cells possess normal CTSB/CATL activity ( Supplementary  Fig. 14b , c) and were fully susceptible to mammalian reoviruses, which use CTSB or CATL for entry ( Supplementary Fig. 14d ). Moreover, these cells remained refractory to in vitro-cleaved rVSV-GP-EboV particles ( Fig. 3c ) that no longer required CTSB/CATL activity within Vero cells ( Supplementary Fig. 14a ). Therefore the HOPS complex and NPC1 are probably required downstream of the initial GP proteolytic processing steps that generate a primed entry intermediate. 
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Finally, we used the intracellular distribution of the internal VSV M (matrix) protein as a marker for membrane fusion (Fig. 3d ). Cells were infected with native VSV or rVSV-GP-EboV and immunostained to visualize the incoming M protein. Endosomal acid-pH-dependent entry of either virus into wild-type HAP1 cells caused redistribution of the incoming viral M throughout the cytoplasm ( Fig. 3d and Supplementary Fig. 15a ). By contrast, only punctate, perinuclear M staining was obtained in drug-treated and mutant cells infected with rVSV-GP-EboV or rVSV-GP-MarV ( Fig. 3d and Supplementary Fig.  15b ). Electron micrographs of mutant cells infected with rVSV-GP-EboV revealed agglomerations of viral particles within vesicular compartments ( Fig. 3e and Supplementary Fig. 16a ) containing LAMP1 ( Supplementary Fig. 16b ), indicating that fusion and uncoating of incoming virus is arrested. Similarly, U18666A treatment increased the number of viral particles in NPC1-and LAMP1-positive endosomes ( Supplementary Fig. 17 ). Therefore, NPC1 and the HOPS complex are required for late step(s) in filovirus entry leading to viral membrane fusion and escape from the lysosomal compartment. 
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We next tested if infection by authentic Ebola virus and Marburg virus is affected in NPC1-mutant primary patient fibroblasts. Yields of viral progeny were profoundly reduced for both viruses in mutant cells (Fig. 4a ). Marked reductions in viral yield were also obtained in Vero cells treated with U18666A ( Fig. 4b ). Moreover U18666A greatly reduced infection of human peripheral blood monocyte-derived dendritic cells and umbilical-vein endothelial cells (HUVECs) (Fig. 4c ), without affecting cell number or morphology ( Supplementary Fig. 19 ). Finally, knockdown of NPC1 in HUVECs diminished infection by filoviruses ( Fig. 4d and Supplementary Fig. 18 ). These findings indicate that NPC1 is critical for authentic filovirus infection.
We assessed the effect of NPC1 mutation in lethal mouse models of Ebola virus and Marburg virus infection. Heterozygous Npc1 (Npc1 1/2 ) knockout mice and their wild-type littermates were challenged with mouse-adapted Ebola virus or Marburg virus and monitored for 28 days. Whereas Npc1 1/1 mice rapidly succumbed to infection with either filovirus, Npc1 1/2 mice were largely protected (Fig. 4e) .
We have used global gene disruption in human cells to discover components of the unusual entry pathway used by filoviruses. Most of the identified genes affect aspects of lysosome function, indicating that filoviruses exploit this organelle differently from all other viruses that we have tested (Fig. 4f ). The unanticipated role for the hereditary disease gene NPC1 in viral entry, infection and pathogenesis may facilitate the development of antifilovirus therapeutics.
METHODS SUMMARY
Adherent HAP1 cells were generated by the introduction of OCT4/SOX2/Myc and KLF4 transcription factors. 100 million cells were mutagenized using a retroviral gene-trap vector. Insertion sites were mapped for approximately 1% of the unselected population using parallel sequencing. Cells were infected with rVSV-GP-EboV and the resistant cell population was expanded. Genes that were statistically enriched for mutation events in the selected population were identified, and the roles of selected genes in filovirus entry were characterized. LETTER RESEARCH METHODS Cells. KBM7 cells and derivatives were maintained in IMDM supplemented with 10% FCS, L-glutamine, and penicillin-streptomycin. Vero cells and primary human dermal fibroblasts (Coriell Institute for Medical Research) were maintained in DMEM supplemented with 10% FCS, L-glutamine and penicillin-streptomycin. Wild-type and NPC1-null (CT43) Chinese hamster ovary (CHO) fibroblasts were maintained in DMEM-Ham's F-12 medium (50-50 mix) supplemented with 10% FCS, L-glutamine and penicillin-streptomycin 30 .
To generate dendritic cells, primary human monocytes were cultured at 37 uC, 5% CO 2 , and 80% humidity in RPMI supplemented with 10% human serum, L-glutamine, sodium pyruvate, HEPES, penicillin-streptomycin, recombinant human granulocyte monocyte-colony stimulating factor (50 ng ml 21 ) and recombinant human interleukin-4 (50 ng ml 21 ) for 6 days. Cytokines were added every 2 days by replacing half of the culture volume with fresh culture media. Dendritic cells were collected on day 6, characterized by flow cytometry (see below) and used immediately. Human umbilical vein endothelial cells (HUVECs) were obtained from Lonza and maintained in endothelial grown medium (EGM; Lonza).
HAP1 cells were used for the haploid screen and fibroblasts or CHO cells were used for hit validation and functional studies. Vero cells are commonly used in studies of filovirus replication, because they are highly susceptible to infection. Dendritic cell and HUVECs resemble cell types that are early and late targets of filovirus infection in vivo, respectively 31, 32 . Flow cytometry of dendritic cells. Human dendritic cells were treated with Fcblock (BD Pharmingen) before incubation with mouse anti-human CD11c-APC (BioLegend) and mouse anti-human CD209-PE or isotype controls. Dendritic cells were washed and re-suspended in PBS for flow cytometric analysis using a BD FACSCanto II flow cytometer (BD Biosciences). Data analysis was completed using FlowJo software. .95% of cells were routinely observed to be CD11c 1 , DC-SIGN 1 . Viruses. Recombinant VSV expressing eGFP and Ebola virus GP (rVSV-GP-EboV) was recovered and amplified as described 10 . Recombinant rVSV-GP-BDV was provided by J. C. de la Torre. rVSV-G-RABV was generated by replacement of the VSV G ORF in VSV-eGFP 33 with that of the SAD-B19 strain of rabies virus, and recombinant virus was recovered and amplified 34 . VSV pseudotypes bearing glycoproteins derived from Ebola virus, Sudan virus and Marburg virus were generated as described 35 .
The following non-recombinant viruses were used: adenovirus type 5 (ATCC), coxsackievirus B1 (ATCC), poliovirus 1 Mahoney (provided by C. Schlieker), HSV-1 KOS (provided by H. Ploegh), influenza A/PR8/34 (H1N1) (Charles Rivers), Rift valley fever virus MP-12 (provided by J. Wojcechowskyj), and mammalian reovirus serotype 1 (provided by M. Nibert). Generation of HAP1 cells. Retroviruses encoding SOX2, MYC, OCT4 and KLF4 were produced 36 . Concentrated virus was used to infect near-haploid KBM7 cells in three consecutive rounds of spin-infection with an interval of 12 h. Colonies were picked and tested for ploidy. One clonally derived cell line (referred to as HAP1) was further grown and characterized. Karyotyping analysis demonstrated that most cells (27 of 39) were fully haploid, a smaller population (9 of 39) was haploid for all chromosomes except chromosome 8, like the parental KBM7 cells. Less than 10% (3 of 39) was diploid for all chromosomes except for chromosome 8, which was tetraploid. Haploid genetic screen. Gene-trap virus was produced in 293T cells by transfection of pGT-GFP, pGT-GFP11 and pGT-GFP12 combined with pAdvantage, CMV-VSVG and Gag-pol. The virus was concentrated using ultracentrifugation for 1.5 h at 25,000 r.p.m. in a Beckman SW28 rotor. 100 million HAP1 cells were infected. A proportion of the cells was harvested for genomic DNA isolation to create a control data set. For the screen, 100 million mutagenized cells were exposed to rVSV-GP-EboV at a MOI ,100. The resistant colonies were expanded and ,30 million cells were used for genomic DNA isolation. Sequence analysis of gene-trap insertion sites. Insertion sites were identified by sequencing the genomic DNA flanking gene-trap proviral DNA as described before 8 . In short, a control data set was generated containing insertion sites in mutagenized HAP1 cells before selection with rVSV-GP-EboV. Genomic DNA was isolated from ,40 million cells and subjected to a linear PCR followed by linker ligation, PCR and sequencing using the Genome Analyser platform (Illumina). Insertion sites were mapped to the human genome and insertion sites were identified that were located in Refseq genes. Insertions in this control data set comprise ,400,000 independent insertions that meet this criteria ( Supplementary  Table 1 ). To generate the experimental data set, insertions in the mutagenized HAP1 cells after selection with rVSV-GP-EboV were identified using an inverse PCR protocol followed by sequencing using the Genome Analyser. The number of inactivating mutations (that is, sense orientation or present in exon) per individual gene was counted as well as the total number of inactivating insertions for all genes. Enrichment of a gene in the screen was calculated by comparing how often that gene was mutated in the screen compared to how often the gene carries an insertion in the control data set. For each gene a P-value (corrected for false discovery rate) was calculated using the one-sided Fisher exact test (Supplementary Table 2 ). Characterization of the HAP1 mutant lines. Genomic DNA was isolated using Qiamp DNA mini kit (Qiagen). To confirm that the cells were truly clonal and to confirm the absence of the wild-type DNA locus, a PCR was performed with primers flanking the insertion site using the following primers: (NPC-F1, 59-GAAGTTGGTCTGGCGATGGAG-39; NPC1-R2, 59-AAGGTCCTGATCTA AAACTCTAG-39; VPS33A-F1, 59-TGTCCTACGGCCGAGTGAACC-39; VPS3 3A-R1, 59-CTGTACACTTTGCTCAGTTTCC-39; VPS11-F1, 59-GAAGGAGCC GCTGAGCAATGATG-39; VPS11-R1, 59-GGCCAGAATTTAGTAGCAGCA AC-39). To confirm the correct insertion of the gene trap at the different loci a PCR was performed using the reverse (R1) primers of NPC1, VPS11 and VPS33A combined with a primer specific for the gene trap vector: PGT-F1; 59-TCT CCAAATCTCGGTGGAAC-39. To determine RNA expression levels of NPC1, VPS11 and VPS33A, total RNA was reverse transcribed using Superscript III (Invitrogen) and amplified using gene-specific primers: VPS11, 59-CTGCTTC CAAGTTCCTTTGC-39 and 59-AAGATTCGAGTGCAGAGTGG-39; NPC1, 59-CCACAGCATGACCGCTC-39 and 59-CAGCTCACAAAACAGGTTCAG-39; VPS33A, 59-TTAACACCTCTTGCCACTCAG-39 and 59-TGTGTCTTTCCTCG AATGCTG-39. Generation of stable cell populations expressing an NPC1-Flag fusion protein. A human cDNA encoding NPC1 (Origene) was ligated in-frame to a triple Flag sequence and the resulting gene encoding a C-terminally Flag-tagged NPC1 protein was subcloned into the pBABE-puro retroviral vector 37 . Retroviral particles packaging the NPC1-Flag gene or no insert were generated by triple transfection in 293T cells, and used to infect control and NPC1-deficient human fibroblasts and CHO lines. Puromycin-resistant stable cell populations were generated. Cell viability assays for virus treatments. KBM7 and HAP1 cells were seeded at 10,000 cells per well in 96-well tissue culture plates and treated with the indicated concentrations of rVSV-GP-EboV. After 3 days cell viability was measured using an XTT colorimetric assay (Roche). Viability is plotted as percentage viability compared to untreated control. To compare susceptibility of the HAP1 mutants to different viruses, they were seeded at 10,000 cells per well and treated with different cytolytic viruses at a concentration that in pilot experiments was the lowest concentration to produce extensive cytopathic effects. Three days after treatment, viable, adherent cells were fixed with 4% formaldehyde in phosphatebuffered saline (PBS) and stained with crystal violet. VSV infectivity measurements. Infectivities of VSV pseudotypes were measured by manual counting of eGFP-positive cells using fluorescence microscopy at 16-26 h after infection, as described previously 5 . rVSV-GP-EboV infectivity was measured by fluorescent-focus assay (FFA), as described previously 10 . Filipin staining. Filipin staining to visualize intracellular cholesterol was done as described 38 . Cells were fixed with paraformaldehyde (3%) for 15 min at 25˚C. After three PBS washes, cells were incubated with filipin complex from Streptomyces filipinensis (Sigma-Aldrich) (50 mg ml 21 ) in the dark for 1 h at room temperature. After three PBS washes, cells were visualized by fluorescence microscopy in the DAPI channel. Measurements of cysteine cathepsin activity. Enzymatic activities of CTSB and CATL in acidified post-nuclear extracts of Vero cells, human fibroblasts and CHO lines were assayed with fluorogenic peptide substrates Z-Arg-Arg-AMC (Bachem Inc.) and (Z-Phe-Arg)2-R110 (Invitrogen) as described 39 . As a control for assay specificity, enzyme activities were also assessed in extracts pre-treated with E-64 (10 mM), a broad-spectrum cysteine protease inhibitor, as previously described 10 . Active CTSB and CATL within intact cells were labelled with the fluorescently labelled activity-based probe GB111 (1 mM) and visualized by gel electrophoresis and fluorimaging, as described previously 40 .
Purification and dye conjugation of rVSV-GP-EboV. rVSV-GP-EboV was purified and labelled with Alexa Fluor 647 (Molecular Probes, Invitrogen Corporation) as described 41 with minor modifications. Briefly, Alexa Fluor 647 (Molecular Probes, Invitrogen Corporation) was solubilized in DMSO at 10 mg ml 21 and incubated at a concentration of 31.25 mg ml 21 with purified rVSV-GP-EboV (0.5 mg ml 21 ) in 0.1 M NaHCO 3 (pH 8.3) for 90 min at room temperature. Virus was separated from free dye by ultracentrifugation. Labelled viruses were resuspended in NTE (10 mM Tris pH 7.4, 100 mM NaCl, 1 mM EDTA) and stored at 280 uC. Virus binding/internalization assay. Cells were inoculated with a MOI of 200-500 of Alexa-647-labelled rVSV-GP-EboV at 4 uC for 30 min to allow binding of virus to the cell surface. Cells were subsequently fixed in 2% paraformaldehyde (to examine virus binding) or after a 2-h incubation at 37 uC and an acid wash to remove surface-bound virus. The cellular plasma membrane was labelled by incubation of RESEARCH LETTER cells with 1 mg ml 21 Alexa Fluor 594 wheat germ agglutinin (Molecular Probes, Invitrogen) in PBS for 15 min at room temperature. External virus particles were detected using a 1:2,000 dilution of antibody 265.1, a mouse monoclonal antibody specific for Ebola GP. The GP antibodies were detected by Alexa-488-conjugated goat anti-mouse secondary antibody (Molecular Probes, Invitrogen). After washing with PBS, cells were mounted onto glass slides using Prolong Antifade Reagent (Invitrogen, Molecular Probes). Fluorescence was monitored with an epifluorescence microscope (Axiovert 200M; Carl Zeiss) equipped with a 363 objective and representative images were acquired using Slidebook 4.2 software (Intelligent Imaging Innovations) 41, 42 . VSV M protein-release assay. Cells grown on 12-mm coverslips coated with poly-D-lysine (Sigma-Aldrich) were pre-treated with 5 mg ml 21 puromycin for 30 min and inoculated with rVSV at a MOI of 200-500 in the presence of puromycin. After 3 h, cells were washed once with PBS and fixed with 2% paraformaldehyde in PBS for 15 min at room temperature. To detect VSV M protein, fixed cells were incubated with a 1:7,500 dilution of monoclonal antibody 23H12 (gift of D. Lyles 43 ) in PBS containing 1% BSA and 0.1% Triton X-100 for 30 min at room temperature. Cells were washed three times with PBS, and the anti-M antibodies were detected using a 1:750 dilution of Alexa 594-conjugated goat anti-mouse secondary antibodies. Cells were counter-stained with DAPI to visualize nuclei. Cells were washed three times and mounted onto glass slides after which M localization images were acquired using a Nikon TE2000-U inverted epifluorescence microscope (Nikon Instruments) equipped with a 320 objective. Representative images were acquired with Metamorph software (Molecular Devices). Electron microscopy. Confluent cell monolayers in 6-well plates were inoculated with rVSV-GP-EboV at a MOI of 200-500 for 3 h. Cells were fixed for at least 1 h at room temperature in a mixture of 2.5% glutaraldehyde, 1.25% paraformaldehyde and 0.03% picric acid in 0.1 M sodium cacodylate buffer (pH 7.4). Samples were washed extensively in 0.1 M sodium cacodylate buffer (pH 7.4) and treated with 1% osmiumtetroxide and 1.5% potassiumferrocyanide in water for 30 min at room temperature. Treated samples were washed in water, stained in 1% aqueous uranyl acetate for 30 min, and dehydrated in grades of alcohol (70%, 90%, 23 100%) for 5 min each. Cells were removed from the dish with propyleneoxide and pelleted at 3,000 r.p.m. for 3 min. Samples were infiltrated with Epon mixed with propyleneoxide (1:1) for 2 h at room temperature. Samples were embedded in fresh Epon and left to polymerize for 24-48 h at 65 uC. Ultrathin sections (about 60-80 nm) were cut on a Reichert Ultracut-S microtome and placed onto copper grids. For preparation of cryosections the virus-inoculated cells were rinsed once with PBS and removed from the dish with 0.5 mM EDTA in PBS. The cell suspension was layered on top of an 8% paraformaldehyde cushion in an Eppendorf tube and pelleted for 3 min at 3,000 r.p.m. The supernatant was removed and fresh 4% paraformaldehyde was added. After 2 h incubation, the fixative was replaced with PBS. Before freezing in liquid nitrogen the cell pellets were infiltrated with 2.3 M sucrose in PBS for 15 min. Frozen samples were sectioned at 2120 uC and transferred to formvar-carbon-coated copper grids. Grids were stained for lysosomes with a mouse monoclonal antibody raised against LAMP1 (H4A3; Santa Cruz Biotechnology). The LAMP1 antibodies were visualized with Protein-A gold secondary antibodies. Contrasting/embedding of the labelled grids was carried out on ice in 0.3% uranyl acetate in 2% methyl cellulose. All grids were examined in a TecnaiG 2 Spirit BioTWIN mission electron microscope and images were recorded with an AMT 2k CCD camera. Authentic filoviruses and infections. Vero cells were pre-treated with culture medium lacking or containing U18666A (20 mM) for 1 h at 37 uC. VERO cells and primary human dermal fibroblasts were exposed to Ebola virus Zaire 1995 or Marburg virus Ci67 at a MOI of 0.1 for 1 h. Viral inoculum was removed and fresh culture media with or without drug was added. Samples of culture supernatants were collected and stored at 280 uC until plaque assays were completed.
Dendritic cells were collected and seeded in 96-well poly-D-lysine-coated black plates (Greiner Bio-One) at 5 3 10 4 cells per well or in 6-well plates at 10 6 cells per well in culture media and incubated overnight at 37 uC. They were pre-treated with medium lacking or containing U18666A as described above. Dendritic cells were exposed to Ebola virus Zaire 1995 or Marburg virus Ci67 at a MOI of 3 for 1 h. Virus inoculum was removed and fresh culture media with or without drug was added. Uninfected cells with or without drug served as negative controls. Cells were incubated at 37 uC and fixed with 10% formalin at designated times. HUVECs were seeded in 96-well poly-D-lysine-coated black plates at 5 3 10 4 cells per well in culture media, treated with U18666A, infected, and processed as described above for dendritic cells. Cytotoxicity analysis. Dendritic cells and HUVECs were seeded in 96-well plates. After overnight incubation at 37 uC, U18666A was added at the same concentrations used for the viral infection studies. Cells in culture media without drug served as the untreated control. At indicated times after treatment, an equal volume of CellTiter-Glo Reagent (Promega) was added to wells containing cells in culture media. Luminescence was measured using a plate reader. Plaque assays for titration of filoviruses. Tenfold serial dilutions of culture supernatants or serum were prepared in modified Eagle's medium with Earle's balanced salts and nonessential amino acids (EMEM/NEAA) plus 5% heat-inactivated fetal bovine serum. Each dilution was inoculated into a well of a 6-well plate containing confluent monolayers of Vero 76 cells. After adsorption for 1 h at 37 uC, monolayers were overlaid with a mixture of 1 part of 1% agarose (Seakem) and 1 part of 23 Eagle basal medium (EBME), 30 mM HEPES buffer and 5% heat-inactivated fetal bovine serum. After incubation at 37 uC, 5% CO 2 , 80% humidity for 6 days, a second overlay with 5% Neutral red was added. Plaques were counted the following day, and titres were expressed as p.f.u. ml 21 . Analysis of filovirus-infected cultures by immunofluorescence. Formalin-fixed cells were blocked with 1% bovine serum albumin solution before incubation with primary antibodies. Ebola-virus-infected cells and uninfected controls were incubated with Ebola virus GP-specific monoclonal antibodies 13F6 (ref. 44) or KZ52 (ref. 45 ). Marburg-virus-infected cells and uninfected controls were incubated with Marburg virus GP-specific monoclonal antibody 9G4. Cells were washed with PBS before incubation with either goat anti-mouse IgG or goat anti-human IgG conjugated to Alexa 488. Cells were counterstained with Hoechst stain (Molecular Probes), washed with PBS and stored at 4 uC. Image analysis. Images were acquired at 9 fields per well with a 310 objective lens on a Discovery-1 high content imager (Molecular Devices) or at 6 fields per well with a 320 objective lens on an Operetta (Perkin Elmer) high content device. Discovery-1 images were analysed with the 'live/dead' module in MetaXpress software. Operetta images were analysed with a customized scheme built from image analysis functions present in Harmony software. Animals and filovirus challenge experiments. Mouse-adapted Ebola virus has been described 46 . Mouse-adapted Marburg virus Ci67 was provided by S. Bavari 47 . Female and male BALB/c Npc1 1/2 mice and BALB/c Npc1 1/1 mice (5-8-weekold) were obtained from Jackson Laboratory. Mice were housed under specific pathogen-free conditions. Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relating to animals and experiments involving animals and adhered to principles stated in the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996) . The facility where this research was conducted is fully accredited by the Association for the Assessment and Accreditation of Laboratory Animal Care International. For infection, mice were inoculated intraperitoneally with a target dose of 1,000 p.f.u. (30,0003 the 50% lethal dose) of mouse-adapted Ebola virus or mouse-adapted Marburg Ci67 virus in a biosafety level 4 laboratory. Mice were observed for 28 days after challenge by study personnel and by an impartial third party. Daily observations included evaluation of mice for clinical symptoms such as reduced grooming, ruffled fur, hunched posture, subdued response to stimulation, nasal discharge and bleeding. Serum was collected from surviving mice to confirm virus clearance. Back titration of the challenge dose by plaque assay determined that Ebola-virus-infected mice received 900 p.f.u. per mouse and Marburg-virusinfected mice received 700 p.f.u. per mouse. RNA interference. Lentiviral vectors expressing an shRNA specific for NPC1 (Sigma-Aldrich; clone# TRCN0000005428; sequence CCACAAGTTCTATAC CATATT) or a non-targeting control shRNA (Sigma-Aldrich; SHC002; sequence CAACAAGATGAAGAGCACCAA) were packaged into HIV-1 pseudotype virus by transfection in HEK 293T cells and lentivirus-containing supernatants were harvested at 36 h and 48 h after transfection and centrifuged onto HUVECs in 12well plates in the presence of 6 mg ml 21 polybrene at 2,500 r.p.m., 25 uC for 90 min. HepG2 cells were transduced as above but without the centrifugation step. Cells were subjected to puromycin selection 24 h after the last lentiviral transduction (HepG2, 1 mg ml 21 ; HUVECs, 1.5 mg ml 21 ) for 48-72 h before harvest for experiments. The level of NPC1 knockdown was assessed by SDS-polyacrylamide gel electrophoresis of cell extracts and immunoblotting with an anti-NPC1 polyclonal antibody (Abcam). Ebola virus replicon assay. Ebola virus support plasmids were created by cloning the NP, VP35, VP30 and L genes from cDNA (provided by E. Mühlberger 48 ) into pGEM3 (Promega) and the mutant pL-D742A plasmid was generated by QuikChange site-directed mutagenesis (Stratagene). Truncated versions of the Ebola virus non-coding sequence were generated by overlap-extension PCR and appended to the eGFP ORF. The replicon pZEm was prepared as described previously 49 . The replicon RNA sequence is flanked on the 59 end by a truncated T7 promoter with a single guanosine nucleotide and on the 39 end by the HDV ribozyme sequence and T7 terminator. The transcribed replicon RNA consists of the following EboV Zaire sequences (GenBank accession AF086833): [59]-single guanosine nucleotide-176-nucleotide genomic 59 terminus-55-nucleotide L mRNA 39 UTR-eGFP ORF (antisense orientation)-100-nucleotide NP mRNA 59 UTR-155-nucleotide genomic 39 terminus- [39] . The viral replicon LETTER RESEARCH
